Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity

American Journal of Epidemiology

Volumn 150, Issue 11, 1999, Pages 1238-1249

  Mossong, Joël ^a,b   Nokes, David James ^a   Edmunds, William John ^a   Cox, Martin John ^a   Ratnam, Samuel ^c   Muller, Claude P ^d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c Newfoundland and Labrador Public Health Laboratory   (Canada)

^d LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

Author keywords

Antibodies, viral; Forecasting; Measles vaccine; Models, statistical; Models, theoretical

Indexed keywords

MEASLES VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; DISEASE TRANSMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEASLES; MEASLES VACCINATION; VACCINATION; VIRUS INFECTION;

EID: 0033485608     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009951     Document Type: Article

References (32)

1. Shasby D, Shope T, Downs H, et al. Epidemic measles in a highly vaccinated population. N Engl J Med 1977;296:585-9.
2. Gustafson TL, Lievens AW, Brunell PA, et al. Measles outbreak in a fully immunized secondary-school population. N Engl J Med 1987;316:771-4.
3. Nkowane BM, Bart SW, Orenstein WA, et al. Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health 1987;77:434-8.
4. Pedersen IR, Mordhorst CH, Glikmann G, et al. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 1989;7:345-8.
5. Boulianne N, Deserres G, Ratnam S, et al. Measles, mumps, and rubella antibodies in children 5-6 years after immunization - effect of vaccine type and age at vaccination. Vaccine 1995;13:1611-16.
6. Farrington CP. The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 1992;21:1014-20.
7. Markowitz LE, Preblud SR, Fine PEM, et al. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990; 9:101-10.
8. Miller C. Live measles-vaccine - a 21 year follow up. BMJ 1987;295:22-4.
9. Edmonson MB, Addiss DG, McPherson JT, et al. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990;263:2466-7.
10. Helfand RF, Kim DK, Gary HE, et al. Nonclassic measles infections in an immune population exposed to measles during a college bus trip. J Med Virol 1998;56:337-41.
11. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody -reevaluation of protective titers. J Infect Dis 1990;162: 1036-42.
12. Huiss S, Damien B, Schneider F, et al. Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Clin Exp Immunol 1997;109: 416-20.
13. Bin D, Chen ZH, Liu QC, et al. Duration of immunity following immunization with live measles-vaccine - 15 years of observation in Zhejiang Province, China. Bull World Health Organ 1991;69:415-23.
14. Muller CP, Huiss S, Schneider F. Secondary immune responses in parents of children with recent measles. Lancet 1996; 348:1379-80.
15. Christenson B, Bottiger M. Measles antibody - comparison of long-term vaccination titers, early vaccination titers and naturally acquired-immunity to and booster effects on the measles-virus. Vaccine 1994;12:129-33.
16. Miller E, Hill A, Morgan-Capner P, et al. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995;13: 799-802.
17. Ratnam S, West R, Gadag V, et al. Immunity against measles in school-aged children: implications for measles revaccination strategies. Can J Public Health 1996;87:407-10.
18. Damien B, Huiss S, Schneider F, et al. Estimated susceptibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons. J Med Virol 1998;56:85-90.
19. Anderson RM, May RM. Infectious diseases of humans. New York: Oxford University Press, 1991.
20. Aaby P, Bukh J, Leerhoy J, et al. Vaccinated children get milder measles infection - a community study from Guinea-Bissau. J Infect Dis 1986;154:858-63.
21. Kawamoto A, Honda T, Ishida K, et al. Two independent outbreaks of measles in partially vaccinated junior high schools in Tottori, Japan. Arch Virol 1995;140:349-54.
22. Rouderfer V, Becker NG, Hethcote HW. Waning immunity and its effects on vaccination schedules. Math Biosci 1994;124: 59-82.
23. Cox MJ, Azevedo RS, Massad E, et al. Measles antibody levels in a vaccinated population in Brazil. Trans R Soc Trop Med Hyg 1998;92:227-30.
24. Ward BJ, Boulianne N, Deserres G, et al. Evidence of immunological priming in measles seronegative children using IgG avidity and IgM responses to revaccination. (Abstract). Clin Infect Dis 1996;23:270.
25. Woolhouse MEJ, Haydon DT, Pearson A, et al. Failure of vaccination to prevent outbreaks of foot-and-mouth-disease. Epidemiol Infect 1996;116:363-71.
26. Moulton LH, Halsey NA. A mixture model with detection limits for regression-analyses of antibody-response to vaccine. Biometrics 1995;51:1570-8.
27. Greene WH. Econometric analysis. 2nd ed. New York: Prentice Hall, 1993.
28. McLean A, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci 1993;253:9-13.
29. Eichner M, Zehnder S, Dietz K. An age-structured model for measles vaccination. In: Isham V, Medley G, eds. Models for infectious human diseases: their structure and relation to data. Cambridge, UK: Cambridge University Press, 1996:38-56.
30. White LJ, Medley GE. Microparasite population dynamics and continuous immunity. Proc R Soc Lond B Biol Sci 1998; 265:1977-83.
31. Draper NR, Smith H. Applied regression analysis. 2nd ed. New York: John Wiley & Sons, 1981.
32. Zar JH. Biostatistical analysis. New York: Prentice-Hall, 1996.